As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...

The company reported total revenues of $13.565 billion, surpassing consensus expectations by 4%, driven by robust sales across key oncology products like Tagrisso, Calquence, and Lynparza. Although ...

KOMET phase III trial of Koselugo shows statistically significant and clinically meaningful ORR vs. placebo in adults with neurofibromatosis type 1: Cambridge, UK Wednesday, Novem ...